This is summary of data presented on MONDAY, March 21, 2016 at the annual meeting of the Society of Gynecologic Oncology, USA.
Genetic testing form DNA from blood or tumors or both from 1,195 women using a gene panel test, BROCA-HR detected that 25.6 percent of the women had a mutation in at least one gene affecting DNA repair.
All of the women who carried mutations in DNA repair genes had significantly better progression-free and overall survival when compared to those with no mutations.
For example, for women with mutations in the BRCA1gene, the Average progression-free survival was 15.7 months, while their overall survival was 55.3 months.
For those with BRCA2mutations, median progression-free survival was 21.6 months, while overall survival was 75.2 months.